Related Experiment Video
Updated: Dec 30, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application
Jing Pang1, David R Sullivan2, Tom Brett3
1School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia.
Insights
Familial hypercholesterolaemia (FH) significantly increases the risk of early heart disease due to high LDL cholesterol. Early detection and new treatments are vital for managing FH and preventing coronary artery disease.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Public Health
Background:
- Familial hypercholesterolaemia (FH) is a genetic disorder causing high LDL cholesterol from birth.
- Untreated FH leads to a substantial risk of premature coronary artery disease (CAD).
- Early detection and intervention are critical for CAD prevention in FH patients.
Purpose of the Study:
- To provide an overview of Familial hypercholesterolaemia.
- To outline recent advances in FH care and management.
- To discuss the prevention of CAD in families affected by FH.
Main Methods:
- Review of recent publications on FH.
- Analysis of data for developing models of care.
- Consideration of new therapeutic strategies for FH.
Main Results:
- Most individuals with FH do not achieve recommended LDL-cholesterol targets with current therapies.
- FH affects approximately 1 in 250 individuals in the community.
- New data supports the development of improved care strategies for FH.
Conclusions:
- Comprehensive strategies are needed for screening, diagnosis, and treatment of FH.
- Advances in FH care offer improved prevention of CAD.
- Future FH care in Australia should align with the National Health Genomics Policy Framework.
Abstract:
Familial hypercholesterolaemia (FH) is caused by a major genetic defect in the low-density lipoprotein (LDL) clearance pathway. Characterised by LDL-cholesterol elevation from birth, FH confers a significant risk for premature coronary artery disease (CAD) if overlooked and untreated. With risk exposure beginning at birth, early detection and intervention is crucial for the prevention of CAD. Lowering LDL-cholesterol with lifestyle and statin therapy can reduce the risk of CAD. However, most individuals with FH will not reach guideline recommended LDL-cholesterol targets. FH has an estimated prevalence of approximately 1:250 in the community. Multiple strategies are required for screening, diagnosing and treating FH. Recent publications on FH provide new data for developing models of care, including new therapies. This review provides an overview of FH and outlines some recent advances in the care of FH for the prevention of CAD in affected families. The future care of FH in Australia should be developed within the context of the National Health Genomics Policy Framework.
More Related Videos
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Genomics
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Polygenic Traits
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Pleiotropy

